Vincamine is a monoterpenoid indole alkaloid found in the leaves of Vinca minor (lesser periwinkle), comprising about 25–65% of its indole alkaloids by weight. It can also be synthesized from related alkaloids.[1]
Clinical data | |
---|---|
Trade names | Oxybral SR |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.015.070 |
Chemical and physical data | |
Formula | C21H26N2O3 |
Molar mass | 354.450 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Vincamine is sold in Europe as a prescription medicine for the treatment of primary degenerative and vascular dementia.[citation needed] In the United States, it is permitted to be sold as a dietary supplement when labeled for use in adults for six months or less.[2] Most common preparations are in the sustained release tablet forms.
Tabersonine can be used for semi-synthesis of vincamine.[3]
Vinpocetine is a synthetic derivative of vincamine used for cerebrovascular diseases and as dietary supplement.[4] Vincamine derivatives have been also studied as anti addictive[5] and antidiabetic[6] agents.
It may have nootropic effects.[3] It has been investigated as novel anticancer drug.[7]
Concerns over long-term use have been documented by the US National Toxicology Program.[8]